Polymorphisms in the genes of GSTP1, ERCC1, XPD, and TS were associated with overall survival in patients with refractory advanced colorectal cancer who received 5-FU/oxaliplatin combination chemotherapy. This evidence concerns the gene TYMS and colorectal cancer.